For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
80
references
 Top references
cited by
4
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      260
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.

          Related collections

          Most cited references80

          • Record: found
          • Abstract: found
          • Article: not found

          Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

          Richard L. Piekarz, Robin Frye, Maria L.C. Turner … (2009)
          PURPOSE Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated. PATIENTS AND METHODS The initial cohort was limited to patients with cutaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sézary syndrome, who had received no more than two prior cytotoxic regimens. There were no limits on other types of therapy. Subsequently, the protocol was expanded to enroll patients who had received more than two prior cytotoxic regimens. Results Twenty-seven patients were enrolled onto the first cohort, and a total of 71 patients are included in this analysis. These patients had undergone a median of four prior treatments, and 62 patients (87%) had advanced-stage disease (stage IIB, n = 15; stage III, n= 6; or stage IV, n = 41). Toxicities included nausea, vomiting, fatigue, and transient thrombocytopenia and granulocytopenia. Pharmacokinetics were evaluated with the first administration of romidepsin. Complete responses were observed in four patients, and partial responses were observed in 20 patients for an overall response rate of 34% (95% CI, 23% to 46%). The median duration of response was 13.7 months. CONCLUSION The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL.
          Article 0 comments Cited 179 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

            Javier Munoz, Amy Musiek, Andrei Shustov … (2018)
            Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of mogamulizumab, a novel monoclonal antibody directed against C-C chemokine receptor 4, with vorinostat in patients with previously treated cutaneous T-cell lymphoma.
            Article 0 comments Cited 175 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

              H Miles Prince, Youn H. Kim, Steven M. Horwitz … (2017)
              Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for previously treated patients with CD30-positive cutaneous T-cell lymphomas.
              Article 0 comments Cited 163 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Sandra I.D. Simões: Role: Academic Editor
                Journal
                Journal ID (nlm-ta): Pharmaceutics
                Journal ID (iso-abbrev): Pharmaceutics
                Journal ID (publisher-id): pharmaceutics
                Title: Pharmaceutics
                Publisher: MDPI
                ISSN (Electronic): 1999-4923
                Publication date (Electronic): 02 February 2021
                Publication date Collection: February 2021
                Volume: 13
                Issue: 2
                Electronic Location Identifier: 200
                Affiliations
                Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan; amagai@ 123456derma.med.tohoku.ac.jp (R.A.); yumi1001@ 123456hosp.tohoku.ac.jp (Y.K.); saiba@ 123456med.tohoku.ac.jp (S.A.)
                Author notes
                [* ]Correspondence: tfujimura1@ 123456med.tohoku.ac.jp ; Tel.: +81-22-717-7271; Fax: +81-22-717-7361
                Article
                Publisher ID: pharmaceutics-13-00200
                DOI: 10.3390/pharmaceutics13020200
                PMC ID: 7913115
                PubMed ID: 33540765
                SO-VID: edd1acb7-20aa-4772-93e9-97506c2e6b2c
                Copyright © © 2021 by the authors.
                License:

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                Date received : 10 November 2020
                Date accepted : 28 January 2021
                Categories
                Subject: Review

                Keywords: ctcl,topical formulation,bexarotene,targeted therapy,interferon,hdac inhibitors
                Data availability:
                Keywords: ctcl, topical formulation, bexarotene, targeted therapy, interferon, hdac inhibitors

                Comments

                Comment on this article

                scite_

                Similar content260

                See all similar

                Cited by4

                See all cited by

                Most referenced authors1,195

                See all reference authors